AOP Orphan Pharmaceuticals GmbH (AOP Health) has established a strategic partnership with VRG Therapeutics Zrt to advance a novel Kv1.3 potassium channel inhibitor for use in inflammation and immunology indications.

UCB SA has entered into a new multiproject strategic alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons, to advance a pipeline of novel investigational oncology candidates.

Apertura Gene Therapy LLC and the TSC Alliance have established a collaboration to advance gene therapy programs designed to treat tuberous sclerosis complex (TSC).

Elaaj Bio, a wholly owned subsidiary of the nonprofit Loulou Foundation, has entered into a partnership with Viralgen Vector Core SL to advance a gene therapy program for CDKL5 deficiency disorder.

Astrazeneca plc has exercised an option under its collaboration with Pinetree Therapeutics Inc. to obtain an exclusive global license to develop and commercialize PTX-299, a first-in-class bispecific antibody degrader targeting EGFR. The option exercise triggers a $25 million payment to Pinetree.

Atrium Therapeutics Inc. has earned a $15 million development milestone payment from Bristol Myers Squibb Co. (BMS) for the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the companies’ ongoing collaboration.

Entos Pharmaceuticals Inc. has established a collaboration with the L-CMD Research Foundation with the aim of developing a curative therapy for LMNA-related congenital muscular dystrophy (L-CMD).

Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. for the use of Alloy’s Anticlastic ASO platform to accelerate the development of innovative oligonucleotide therapeutics.

Akari Therapeutics plc has established a strategic partnership with Wuxi XDC Cayman Inc. to accelerate the development of Akari’s novel PH1 payload. Akari’s lead program, AKTX-101, is initially targeting metastatic urothelial cancer.